Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Aditi Kadakia, Brenna L. Brady, Carole Dembek, G. Rhys Williams & Justine M. Kent. (2022) The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population. Journal of Medical Economics 25:1, pages 87-98.
Read now
Read now
Khalid Orayj. (2021) Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinson’s Disease Patients: A Population-Based Study. Risk Management and Healthcare Policy 14, pages 2443-2452.
Read now
Read now
Abeer M. Abd El-Hameed, Areej A. Eskandrani & Fadwa A. Elroby. (2020) Assessment of the ameliorative effect of Hypericum perforatum on olanzapine-induced hepatic oxidative stress and metabolic abnormalities in experimental male albino rats. Journal of Taibah University for Science 14:1, pages 1496-1502.
Read now
Read now
Nazan Aydın, Hasan Mervan Aytaç, Esra Yazıcı, Doğan Yılmaz, Pınar Çetinay Aydın, Gökşen Yüksel Yalçın, Yücel Kadıoğlu, Cana Canbay, Merve Terzioğlu, Onur Şenol, Cavide Çakmak & Aysel Özer. (2019) Rediscovery of penicillin of psychiatry: haloperidol decanoate. Psychiatry and Clinical Psychopharmacology 29:3, pages 264-275.
Read now
Read now
Cüneyt Ünsal, Yakup Albayrak, Neslihan Albayrak, Murat Kuloglu & Kenji Hashimoto. (2013) Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine. Neuropsychiatric Disease and Treatment 9, pages 1545-1552.
Read now
Read now
Srihari Gopal, Yanning Liu, Larry Alphs, Adam Savitz, Isaac Nuamah & David Hough. (2013) Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatric Disease and Treatment 9, pages 1381-1392.
Read now
Read now
Cynthia V. Calkin, David M. Gardner, Thomas Ransom & Martin Alda. (2013) The relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders. Annals of Medicine 45:2, pages 171-181.
Read now
Read now
Ann Pearman & Abhinandan Batra. (2012) Late-Onset Schizophrenia: A Review for Clinicians. Clinical Gerontologist 35:2, pages 126-147.
Read now
Read now
Mehmet GÖkŞin Karaman, Ayten ErdoĞan, Evren Tufan, Nihal Yurteri, Esra Özdemir & Handan Ankarali. (2011) Liver function tests in children and adolescents receiving risperidone treatment for a year: A longitudinal, observational study from Turkeya. International Journal of Psychiatry in Clinical Practice 15:3, pages 204-208.
Read now
Read now
Maurizio Pompili, Gianluca Serafini, Marco Innamorati, Elisa Ambrosi, Ludovica Telesforo, Paola Venturini, Gloria Giordano, Michele Battuello, David Lester & Paolo Girardi. (2011) Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?. Expert Review of Neurotherapeutics 11:7, pages 989-1006.
Read now
Read now
Gin Malhi, Danielle Adams, Janice Plain, Carissa Coulston, Michael Herman & Garry Walter. (2010) Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context. Australasian Psychiatry 18:1, pages 32-41.
Read now
Read now
Andrew J Cutler. (2009) Iloperidone: a new option for the treatment of schizophrenia. Expert Review of Neurotherapeutics 9:12, pages 1727-1741.
Read now
Read now
Adriana Foster, Zixuan Wang, Manzoor Usman, Edna Stirewalt & Peter Buckley. (2007) Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians. Neuropsychiatric Disease and Treatment 3:6, pages 965-973.
Read now
Read now